Figure 2.
Selected pharmacological interventions with positive effects in animal models of CIBP: Trk inhibitor (ARRY-470);79 BDNF siRNA;82 P2X3 antagonist (AF-353);138 TRPV1 antagonist (JNJ-17203212);125 IL-1 receptor antagonist (anakinra);103 anti-MCP-1 antibody;114 anti-CX3CR1 antibody;110,111 anti-TNFα antibody (etanercept);27 anti-NGF antibody;75,77 sulfasalzine;87 thalidomide;105 gabapentin;179 opioids (morphine, oxycodone);180,181 alendronate;177 cisplatin + 89SR;182 anti-RANKL antibody (denosumab);183 Cox-2 inhibitor (MF tricyclic);20 zoledronic acid;176 p38 MAPK inhibitor (SB203580);184 osteoprotegerin;41,42 CB2 agonist (JWH015);101 ibandronate;44,45 risedronate;44,46 anti-PTHrP antibody;56 cathepsin K inhibitor;178 TGFβ type I receptor kinase inhibitor (LY2109761);57 and chemotherapeutics. Trk inhibitor, tropomyosin receptor kinase inhibitor; BDNF siRNA, brain-derived neurotrophic factor small interfering RNA; P2X3 antagonist, P2X purinoceptor 3 antagonist; TRPV1 antagonist, transient receptor potential vanilloid type 1 antagonist; IL-1 receptor antagonist, interleukin-1 receptor antagonist; anti-MCP-1 antibody, anti-monocyte chemoattractant protein-1 antibody; anti-CX3CR1 antibody, anti-fractalkine receptor antibody; anti-TNFα antibody, antitumor necrosis factor-α antibody; anti-NGF antibody, anti-nerve growth factor antibody; anti-RANKL antibody, anti-receptor activator of nuclear factor κB ligand antibody; CB2 agonist, cannabinoid receptor 2 agonist; anti-PTHrP antibody, anti-parathyroid hormone related protein antibody.